Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder

 Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced Health Canada approval for a phase 2 clinical trial at the University of British Columbia (UBC). The trial will study the effects of PEX010, Filament’s botanical psilocybin drug candidate, for the treatment of opioid use disorder (OUD).

“Opioid use disorder is one of the most challenging public health issues and a major contributor to the escalating overdose crisis in Canada. This trial will assess the safety and feasibility of delivering psilocybin in the treatment of OUD, and evaluate potential changes in participants’ opioid use. We are grateful to Filament Health for funding and facilitating this trial.”

-Dr. Christian Schütz, Professor of Psychiatry at UBC and Principal Investigator for the trial

Standard treatment for OUD is opioid agonist therapy (OAT). But less than half of those who start OAT remain for 6 months, and approximately 1 in 10 patients receiving professional help due to an overdose were receiving OAT. There is a critical need for research into new interventions to support those with OUD, and research indicates that psychedelic-assisted therapy may be a promising approach.

“This is a landmark moment in Filament’s mission to support the treatment of substance use disorders with naturally-derived psychedelics. As a Vancouver-based company, we are quite aware of the ongoing toxic drug crisis fuelled by OUD. We are proud to sponsor this much-needed research by Dr. Schütz and his team.”

-Benjamin Lightburn, Chief Executive Officer and Co-Founder of Filament Health

ABOUT FILAMENT HEALTH

 (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.

Original Source